• Print
  • PDF version
  • Contact


ABL acquires CDL Pharma to develop CRO-related services and assays manufacturing capacity

LUXEMBOURG, July 04, 2018, Advanced Biological Laboratories (ABL - https://www.ablsa.com) announced today that it has signed a definitive agreement to acquire CDL Pharma.

This aquisition adds powerful capabilities for centralized biological analyses and molecular diagnostics assays manufacturing.

This is a natural evolution of ABL expertise which will help consolidating and developing its products and services portfolio around clinical data management (Nadis® platform technology) and around the manufacturing of molecular biology products including DNA/RNA sequencing for genotyping and drug resistance determination (DeepChek®) and quantification (UltraGene®) assays (viral load) for microbiology applications like HIV, HBV, HCV, CMV, Tuberculosis, HPV, 16s RNA…

Read more